VieCure

Moat is the content library, which is this index's most used grading precedent. VieCure's differentiating asset is a codified clinical knowledge base the company reports at more than 5,000 rules, plus a licence to NCCN treatment templates, sitting inside an oncology electronic medical record that functions as a system of record regardless of what reasons over it. The inference engine applies codified rules to patient specific data, which is legitimately artificial intelligence in the expert system sense and is not machine learning, and the company's own language says so: codified clinical content, codified rules, clinical inference engine. That is a precision worth recording rather than an accusation of inflation, because rules based inference over curated guidelines is a defensible architecture for oncology and arguably a safer one. But the durable asset a competitor could not easily replicate is the curated content and the NCCN relationship, not a model. Same reasoning applied to Reveleer and the credentialing lane.

The architecture supports oversight well and the disclosure stops short of demonstrating it. Output is positioned as point of care decision support: the system generates a personalised treatment plan and the oncologist adopts, modifies or rejects it, and plans are continuously monitored and updated as the patient's state changes. Because reasoning runs over codified rules rather than a learned model, any given recommendation is in principle traceable to the rule and the guideline behind it, which is a stronger oversight property than an opaque score. What is not published: how often clinicians override recommendations, what the system does when a patient's situation falls outside the codified pathways, which is common in oncology, how rule conflicts resolve, and how quickly the library is updated when a guideline changes. That last question is load bearing for a product whose value rests on currency of content.

Better than most clinical decision support vendors because VieCure names its knowledge source rather than hiding behind a model. The NCCN licensing agreement means a clinician can trace a substantial part of any recommendation back to a published guideline they can independently read and disagree with, which is the same structural property that earns Avo credit in this index and that anchors Nym Health's coding approach to published AMA and CMS guidance rather than to institutional patterns. The company also states the scale and composition of the rule base and describes the inference architecture in general terms. Held at B because the curation methodology is undisclosed: who authors and reviews non NCCN rules, what evidence standard admits a rule, how the New Century Pathways and other licensed content are reconciled with NCCN where they diverge, and what the patented AI engine actually does beyond rule evaluation.

Substantial deployment, no published outcomes. VieCure names real customers at real scale, including American Oncology Network, The Oncology Institute, Oncology Care Partners and Summit Cancer Centers, and reports more than 18,000 patients managed daily across a network exceeding 100 community cancer centre locations. What does not exist publicly is any measurement of whether the platform changes anything. No peer reviewed study, no guideline adherence rate before and after adoption, no variability reduction figure, no outcome or survival data, and no comparison against practices using conventional tools. For a product whose central claim is reducing unwarranted variation in cancer treatment, guideline concordance is the obvious measurable endpoint and it is not reported. Graded C on the standing precedent that deployment scale does not substitute for evidence of benefit.

No published statement on patient data handling, retention, de identification, secondary use or model and rule improvement using customer data was located. The platform is the oncology system of record for its customers and holds an analytics environment the company describes as spanning more than 17,000 fields of patient data including demographics, medical history, diagnostics, interventions, treatment history, disease profiles and outcomes, so the stewardship question is large. Nothing public addresses it in either direction.

No HIPAA compliance statement or business associate agreement terms were located. As the electronic medical record for United States community oncology practices, VieCure necessarily operates under such agreements, but nothing publicly verifiable was found.

No SOC 2, HITRUST, ISO 27001 or equivalent attestation, and no trust centre or security documentation, was located publicly. Notable by absence given the product is a system of record holding complete oncology records rather than a point tool sitting alongside one.

No device authorisation and no published regulatory position, and this is the highest stakes scoping question among the vendors assessed on this sourcing list. The product generates personalised CANCER TREATMENT PLANS at the point of care, which is squarely the territory the clinical decision support exclusions under the 21st Century Cures Act were written to delimit. The exclusion turns on whether a clinician can independently review the basis for the recommendation rather than relying on it, and VieCure's architecture gives it the strongest available argument: recommendations derive from codified rules traceable to NCCN guidelines a physician can read. That argument is available and the company has not made it publicly. Ask for the documented regulatory analysis rather than inferring it from the architecture, and ask specifically how the position holds for recommendations drawn from non NCCN codified content where the underlying source is not independently publishable.

No fairness, subgroup or equity disclosure was located, and two specific issues sit underneath that absence. The first is inherited: NCCN guidelines and the precision oncology evidence base rest substantially on trial populations that underrepresent Black, Hispanic and older patients, so a system that faithfully implements published guidance also faithfully inherits the representation gaps in the evidence behind it. A rules based architecture does not create that bias but it does propagate it consistently and at scale, and nothing published acknowledges the limitation. The second is structural and more concerning. VieCure states that its rule base includes PAYER RULES alongside clinical plans, pathways, protocols and formularies, and separately markets cost optimisation through algorithmic molecular testing decision support. A single engine blending clinical guidance with coverage and cost logic must make clear which is which, because a clinician viewing a recommended plan cannot otherwise tell whether an option is absent for clinical reasons or reimbursement ones. That distinction is the difference between decision support and utilisation management, and no disclosure separating them was located. It should be the first question a practice asks.

VieCure does not integrate with the oncology record, it IS the oncology record, which changes the shape of this axis. Within its footprint the consolidation is genuinely deep: medical records, treatment planning, imaging, labs, next generation sequencing, molecular pathology and medical, radiation and surgical oncology in one system, with physician and patient mobile applications and an analytics environment on top. The company states a flexible approach allowing integration with existing systems and multiple data sources, and reports implementing at a new customer within 60 days. Held at B because no external EHR, standard or named integration partner appears anywhere public, and for a practice inside a larger health system the question of how VieCure coexists with the enterprise record, and who holds the source of truth, is unanswered.

Cloud based by the company's own description, with mobile applications for physicians and patients. No hosting provider, region, tenancy model, residency commitment or single tenant option is published, which is a gap of some weight for a product acting as the system of record for a practice's entire oncology population.

No price, tier or licensing unit is published. The unit question is consequential for a combined record system and decision support platform: per provider, per practice, per patient under management and per location produce very different economics for a network growing by acquisition, which is exactly how several named customers are expanding. Partial credit for one disclosed operational commitment, a stated 60 day implementation timeline at a named new customer, which is more than most enterprise platforms will put in writing. VieCure also provides implementation services and ongoing support alongside the software, and whether those are bundled or separately charged is not stated.

Deliberately and coherently narrow. The target is COMMUNITY oncology rather than academic cancer centres, and the company's stated purpose is closing the gap between the two, which is a real and defensible problem since most United States cancer care is delivered in community settings while precision oncology expertise concentrates elsewhere. Within oncology the coverage is broad, spanning medical, radiation and surgical disciplines across the continuum from diagnosis through therapy to survivorship, at more than 100 locations. The boundaries: single disease area, ambulatory rather than inpatient, United States only, and the platform is a system of record commitment rather than an adjunct tool, so it is not an option for a practice unwilling to change its EMR.